Literature DB >> 29967423

Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.

Rachel Pearlman1, Michael Markow2, Deborah Knight2, Wei Chen2, Christina A Arnold2, Colin C Pritchard3, Heather Hampel1, Wendy L Frankel4.   

Abstract

Universal screening for Lynch syndrome in colorectal cancer is recommended, and immunohistochemistry for the mismatch repair proteins is commonly used. To reduce cost, some screen using only MSH6 and PMS2, with reflex to the partner stain if either are absent (two-stain method). An expression pattern revealing absent MSH2 and intact MSH6 is not expected, but could result in failed Lynch syndrome detection. We analyzed tumors with absent MSH2 but any degree of MSH6 expression to determine if the two-stain method could miss MSH2 mutations. One-thousand seven-hundred thirty colorectal cancer patients from the Ohio Colorectal Cancer Prevention Initiative underwent tumor screening using microsatellite instability and immunohistochemistry. The two-stain method was used for 1235 cases; staining for all four proteins was completed for 495 cases. The proportion of positive cells and staining intensity were reviewed for MSH6, as well as MSH2 when available. Patients with mismatch repair deficiency underwent next-generation sequencing of germline DNA for mismatch repair genes. If negative, tumor next-generation sequencing was performed to assess for somatic mutations. Overall, thirty-three (1.9%, 33/1730) MSH2-absent cases were identified. Of those, fourteen had no MSH6 expression but eight (0.5%, 8/1730) had ambiguous and eleven (0.6%, 11/1730) had convincing MSH6 expression that could have been interpreted as intact. Germline next-generation sequencing identified MSH2 mutations in 11/14 cases with absence of both stains, 7/8 cases with ambiguous MSH6 expression, and 9/11 cases with convincing MSH6 expression. All remaining cases, except one, had double somatic mutations. The two-stain method fails to detect some patients with Lynch syndrome: (1) significant staining weaker than the control may be incorrectly interpreted as intact MSH6, or (2) Weak or focal/patchy MSH6 can be retained with the absence of MSH2. Accordingly, we recommend the four-stain method be used for optimal Lynch syndrome screening detection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29967423      PMCID: PMC6800091          DOI: 10.1038/s41379-018-0058-y

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

1.  A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas.

Authors:  Amirkaveh Mojtahed; Iris Schrijver; James M Ford; Teri A Longacre; Reetesh K Pai
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

2.  Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps.

Authors:  Matthew B Yurgelun; Ajay Goel; Jason L Hornick; Ananda Sen; Danielle Kim Turgeon; Mack T Ruffin; Norman E Marcon; John A Baron; Robert S Bresalier; Sapna Syngal; Dean E Brenner; C Richard Boland; Elena M Stoffel
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-18

3.  How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?

Authors:  Alex Vilkin; Marisa Halpern; Sara Morgenstern; Eli Brazovski; Rachel Gingold-Belfer; Doron Boltin; Ofer Purim; Yulia Kundel; Sara Welinsky; Baruch Brenner; Yaron Niv; Zohar Levi
Journal:  Hum Pathol       Date:  2014-07-23       Impact factor: 3.466

Review 4.  Hereditary nonpolyposis colorectal cancer--Lynch syndromes I and II.

Authors:  H T Lynch; S J Lanspa; B M Boman; T Smyrk; P Watson; J F Lynch; P M Lynch; G Cristofaro; P Bufo; A V Tauro
Journal:  Gastroenterol Clin North Am       Date:  1988-12       Impact factor: 3.806

5.  Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel.

Authors:  Toni O'Regan; Kai Chau; Michael Tatton; Tania Smith; Susan Parry; Ian Bissett
Journal:  N Z Med J       Date:  2013-09-13

6.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

7.  Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.

Authors:  Rondell P Graham; Sarah E Kerr; Malinda L Butz; Stephen N Thibodeau; Kevin C Halling; Thomas C Smyrk; Michelle A Dina; Victoria M Waugh; Kandelaria M Rumilla
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

8.  ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Authors:  Colin C Pritchard; Christina Smith; Stephen J Salipante; Ming K Lee; Anne M Thornton; Alex S Nord; Cassandra Gulden; Sonia S Kupfer; Elizabeth M Swisher; Robin L Bennett; Akiva P Novetsky; Gail P Jarvik; Olufunmilayo I Olopade; Paul J Goodfellow; Mary-Claire King; Jonathan F Tait; Tom Walsh
Journal:  J Mol Diagn       Date:  2012-05-30       Impact factor: 5.568

Review 9.  EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.

Authors:  Glenn E Palomaki; Monica R McClain; Stephanie Melillo; Heather L Hampel; Stephen N Thibodeau
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

10.  Development of a fluorescent multiplex assay for detection of MSI-High tumors.

Authors:  Jeffery W Bacher; Laura A Flanagan; Regenia L Smalley; Nadine A Nassif; Lawrence J Burgart; Richard B Halberg; Wael M Abdel Megid; Stephen N Thibodeau
Journal:  Dis Markers       Date:  2004       Impact factor: 3.434

View more
  15 in total

Review 1.  MSI testing : What's new? What should be considered?

Authors:  Josef Rüschoff; Gustavo Baretton; Hendrik Bläker; Wolfgang Dietmaier; Manfred Dietel; Arndt Hartmann; Lars-Christian Horn; Korinna Jöhrens; Thomas Kirchner; Ruth Knüchel; Doris Mayr; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Katharina Tiemann; Wilko Weichert; Reinhard Büttner
Journal:  Pathologe       Date:  2021-09-03       Impact factor: 1.011

2.  Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis.

Authors:  K T S Aiyer; T Doeleman; N A Ryan; M Nielsen; E J Crosbie; V T H B M Smit; H Morreau; J J Goeman; T Bosse
Journal:  Mod Pathol       Date:  2022-09-14       Impact factor: 8.209

Review 3.  [MSI testing : What is new? What should be considered? German version].

Authors:  Josef Rüschoff; Gustavo Baretton; Hendrik Bläker; Wolfgang Dietmaier; Manfred Dietel; Arndt Hartmann; Lars-Christian Horn; Korinna Jöhrens; Thomas Kirchner; Ruth Knüchel; Doris Mayr; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Katharina Tiemann; Wilko Weichert; Reinhard Büttner
Journal:  Pathologe       Date:  2021-05-27       Impact factor: 1.011

4.  Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method.

Authors:  Ioanna Gazouli; George Zarkavelis; Davide Mauri; George Pentheroudakis
Journal:  Ann Transl Med       Date:  2019-12

5.  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.

Authors:  Elena Fountzilas; Vassiliki Kotoula; George Pentheroudakis; Kyriaki Manousou; Genovefa Polychronidou; Eleni Vrettou; Christos Poulios; Eirini Papadopoulou; Georgia Raptou; Eirini Pectasides; Georgia Karayannopoulou; Sofia Chrisafi; Pavlos Papakostas; Thomas Makatsoris; Ioannis Varthalitis; Amanda Psyrri; Epaminontas Samantas; Mattheos Bobos; Christos Christodoulou; Christos Papadimitriou; George Nasioulas; Dimitrios Pectasides; George Fountzilas
Journal:  ESMO Open       Date:  2019-03-12

Review 6.  Lynch Syndrome: Its Impact on Urothelial Carcinoma.

Authors:  Andrea Katharina Lindner; Gert Schachtner; Gennadi Tulchiner; Martin Thurnher; Gerold Untergasser; Peter Obrist; Iris Pipp; Fabian Steinkohl; Wolfgang Horninger; Zoran Culig; Renate Pichler
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

7.  Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.

Authors:  Xin-Yu Ren; Yu Song; Jing Wang; Long-Yun Chen; Jun-Yi Pang; Liang-Rui Zhou; Song-Jie Shen; Xi Cao; Yu-Xin Wang; Miao-Miao Shao; Zhi-Yong Liang; Qiang Sun; Huan-Wen Wu
Journal:  Front Oncol       Date:  2021-03-04       Impact factor: 6.244

8.  Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.

Authors:  Rachel Pearlman; Wendy L Frankel; Benjamin J Swanson; Dan Jones; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Thomas W Prior; Mitchell Haut; Matthew F Kalady; Brandie Heald; Ian Paquette; David J Draper; Joanna M Brell; Sameer Mahesh; Kisa Weeman; Shyamal Bastola; Jeffrey Zangmeister; Aruna Gowda; Filix Kencana; Albert Malcolm; Yinong Liu; Sharon Cole; Charles Bane; Chaoyang Li; Esther Rehmus; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Shelly A Cummings; Albert de la Chapelle; Heather Hampel
Journal:  JCO Precis Oncol       Date:  2021-05-05

9.  Genetic testing for inherited colorectal cancer and polyposis, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Rong Mao; Patti Krautscheid; Rondell P Graham; Arupa Ganguly; Suma Shankar; Matthew Ferber; Madhuri Hegde
Journal:  Genet Med       Date:  2021-06-17       Impact factor: 8.822

10.  Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome.

Authors:  Lin Dong; Shuangmei Zou; Xianglan Jin; Haizhen Lu; Ye Zhang; Lei Guo; Jianqiang Cai; Jianming Ying
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.